[go: up one dir, main page]

WO2004060270A8 - Compositions and methods for the diagnosis and treatment of tumor - Google Patents

Compositions and methods for the diagnosis and treatment of tumor

Info

Publication number
WO2004060270A8
WO2004060270A8 PCT/US2003/029126 US0329126W WO2004060270A8 WO 2004060270 A8 WO2004060270 A8 WO 2004060270A8 US 0329126 W US0329126 W US 0329126W WO 2004060270 A8 WO2004060270 A8 WO 2004060270A8
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
diagnosis
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/029126
Other languages
French (fr)
Other versions
WO2004060270A2 (en
Inventor
Thomas D Wu
Yan Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to AU2003303144A priority Critical patent/AU2003303144A1/en
Priority to CA002503043A priority patent/CA2503043A1/en
Priority to JP2004564724A priority patent/JP2006516192A/en
Priority to EP03813488A priority patent/EP1578996A4/en
Publication of WO2004060270A2 publication Critical patent/WO2004060270A2/en
Anticipated expiration legal-status Critical
Publication of WO2004060270A8 publication Critical patent/WO2004060270A8/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/US2003/029126 2002-10-18 2003-10-15 Compositions and methods for the diagnosis and treatment of tumor Ceased WO2004060270A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003303144A AU2003303144A1 (en) 2002-10-18 2003-10-15 Compositions and methods for the diagnosis and treatment of tumor
CA002503043A CA2503043A1 (en) 2002-10-18 2003-10-15 Compositions and methods for the diagnosis and treatment of tumor
JP2004564724A JP2006516192A (en) 2002-10-18 2003-10-15 Compositions and methods for tumor diagnosis and treatment
EP03813488A EP1578996A4 (en) 2002-10-18 2003-10-15 Compositions and methods for the diagnosis and treatment of tumor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41898802P 2002-10-18 2002-10-18
US60/418,988 2002-10-18

Publications (2)

Publication Number Publication Date
WO2004060270A2 WO2004060270A2 (en) 2004-07-22
WO2004060270A8 true WO2004060270A8 (en) 2005-07-14

Family

ID=32712943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/029126 Ceased WO2004060270A2 (en) 2002-10-18 2003-10-15 Compositions and methods for the diagnosis and treatment of tumor

Country Status (5)

Country Link
EP (1) EP1578996A4 (en)
JP (1) JP2006516192A (en)
AU (1) AU2003303144A1 (en)
CA (1) CA2503043A1 (en)
WO (1) WO2004060270A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065006A2 (en) * 2002-01-31 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
EP1562969A4 (en) * 2002-03-28 2006-07-05 Bristol Myers Squibb Co Novel human cell surface protein with immunoglobulin folds, bgs-19
CA2483436A1 (en) * 2002-04-23 2003-11-06 University Of Georgia Research Foundation, Inc. N-acetylglucosaminyltransferase vb coding sequence, recombinant cells and methods
JP2005230011A (en) 2004-02-20 2005-09-02 Samsung Electronics Co Ltd Breast cancer-related protein, gene encoding the same, and protein and diagnostic method for breast cancer using the gene
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
DK2319925T3 (en) 2004-08-16 2018-11-05 Quark Pharmaceuticals Inc Therapeutic applications of RTP801 inhibitors
GB0422211D0 (en) * 2004-10-06 2004-11-03 Randox Lab Ltd Method
US20080145369A1 (en) * 2004-10-13 2008-06-19 Ginette Serrero Autocrine Growth Factor Receptors and Methods
JP2007008844A (en) * 2005-06-29 2007-01-18 Nippon Flour Mills Co Ltd Monoclonal antibody specifically reacting with septin 2 protein, hybridoma producing the same, cancer detection method and cancer detection kit
DOP2007000015A (en) 2006-01-20 2007-08-31 Quark Biotech Inc THERAPEUTIC USES OF RTP801 INHIBITORS
US20070237713A1 (en) 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
US7723052B2 (en) 2006-05-11 2010-05-25 Quark Pharmaceuticals, Inc. Screening systems utilizing RTP801
AU2007253740A1 (en) * 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
EP2026843A4 (en) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc Therapeutic uses of inhibitors of rtp801l
EP2137205A2 (en) 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
WO2008148072A2 (en) * 2007-05-24 2008-12-04 The Brigham And Women's Hospital, Inc. Disease-associated genetic variations and methods for obtaining and using same
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
EP2334790A1 (en) * 2008-08-27 2011-06-22 Oncotherapy Science, Inc. Pancreatic cancer related gene ttll4
KR20110128316A (en) 2009-02-20 2011-11-29 가니메드 파마슈티칼스 아게 Methods and Compositions for Diagnosis and Treatment of Cancer
NO2499161T3 (en) 2009-11-11 2018-02-03
WO2011150400A1 (en) * 2010-05-28 2011-12-01 New York Blood Center, Inc. Nuclear scaffold protein stip/tfip11 target for cancer therapy
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
NZ724296A (en) 2011-05-13 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
AP2015008365A0 (en) 2012-12-05 2015-04-30 Novartis Ag Compositions and methods for antibodies targeting epo
ES3032013T3 (en) * 2013-03-15 2025-07-14 Translate Bio Inc Synergistic enhancement of the delivery of nucleic acids via blended formulations
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP2018525389A (en) 2015-08-12 2018-09-06 ノバルティス アーゲー How to treat eye disorders
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
MX2019014027A (en) 2017-05-24 2020-08-03 Thoeris Gmbh Use of glutamine synthetase for treating hyperammonemia.
EP3856226A1 (en) 2018-09-28 2021-08-04 President and Fellows of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
JP7766904B2 (en) * 2021-06-04 2025-11-11 地方独立行政法人東京都健康長寿医療センター Pharmaceutical composition for treating prostate cancer
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8678501A (en) * 2000-08-24 2002-03-04 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
KR20040014392A (en) * 2000-08-24 2004-02-14 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
EP1445317A3 (en) * 2000-08-24 2004-12-15 Genentech Inc. Compositions and methods for the diagnosis and treatment of tumor

Also Published As

Publication number Publication date
JP2006516192A (en) 2006-06-29
EP1578996A4 (en) 2007-12-19
EP1578996A2 (en) 2005-09-28
AU2003303144A1 (en) 2004-07-29
CA2503043A1 (en) 2004-07-22
WO2004060270A2 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A4 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1572091A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1553912A4 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
AU2003290605A1 (en) Compositions and methods for the diagnosis and treatment of sepsis
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002359330A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003303144

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003813488

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2503043

Country of ref document: CA

Ref document number: 2004564724

Country of ref document: JP

D17 Declaration under article 17(2)a
WWP Wipo information: published in national office

Ref document number: 2003813488

Country of ref document: EP